10-K: Amarin Navigates Global Expansion Amidst US Generic Headwinds

Amarin Corporation plc reports a 7% decrease in total revenue for 2025, driven by declining U.S. VASCEPA sales amidst generic competition, while advancing international commercialization and restructuring efforts.

Summary

• Total revenue, net, decreased by $15.0 million (7%) to $213.6 million in 2025 from $228.6 million in 2024.
• U.S. product revenue, net, declined by 8% to $154.1 million in 2025 from $166.7 million in 2024, primarily due to a decrease in net selling price from generic competition.
• Amarin's share of the U.S. icosapent ethyl market decreased to approximately 47% in 2025 from 53% in 2024, despite the overall market increasing by 2%.
• VASCEPA-branded prescriptions in the U.S. decreased by 10% in 2025 compared to 2024.
• Licensing and royalty revenue increased by $6.9 million (29%) to $30.9 million in 2025, primarily due to a $25.0 million upfront payment from the Recordati Licensing Agreement.
• Cost of goods sold decreased by $54.5 million (37%) to $92.8 million in 2025, partly due to a $36.5 million restructuring inventory charge in 2024 not recurring at the same magnitude in 2025.
• Gross margin on product sales improved to 49% in 2025 from 28% in 2024 (excluding restructuring inventory and write-off charges, gross margin was 49% in 2025 and 50% in 2024).
• Selling, general and administrative expense decreased by $37.3 million (24%) to $115.0 million in 2025, mainly due to cost reductions from the Global Restructuring Plan.
• Research and development expense decreased by $1.1 million (5%) to $19.8 million in 2025.
• A global restructuring plan was announced in June 2025, expected to reduce operating costs by approximately $70 million annually, primarily from eliminating European commercial roles.
• Net loss for 2025 was $38.8 million, compared to $82.2 million in 2024 and $59.1 million in 2023.
• Cash and cash equivalents and short-term investments totaled $302.6 million as of December 31, 2025.
• The company has an accumulated deficit of $1.7 billion as of December 31, 2025.
• VASCEPA/VAZKEPA has received marketing authorization and is being commercialized or is under regulatory review in numerous countries outside the U.S., including Europe, Canada, China, Australia, New Zealand, Middle East, North Africa, South Korea, and Israel.
• In Europe, VAZKEPA has 10 years of market protection, with a patent issued in April 2024 extending exclusivity to 2039.
• The U.S. Supreme Court granted Hikma's petition to review a Federal Circuit decision regarding patent infringement litigation, staying District Court proceedings.
• Amarin is a defendant in six antitrust class action lawsuits and is cooperating with DOJ and New York Attorney General investigations related to promotional speaker programs and co-payment waiver programs.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for Amarin, marked by significant U.S. revenue decline and ongoing litigation, partially offset by strategic international expansion and cost-saving measures.

Positives

• Licensing and royalty revenue increased by 29% to $30.9 million in 2025, driven by a $25.0 million upfront payment from the Recordati Licensing Agreement.
• Gross margin on product sales improved significantly to 49% in 2025 from 28% in 2024 (or 49% vs 50% excluding restructuring charges), indicating better cost management or product mix.
• Selling, general and administrative expenses decreased by 24% ($37.3 million) in 2025 due to the Global Restructuring Plan and other cost optimization initiatives, expected to yield $70 million in annual savings.
• Net cash provided by operating activities increased to $6.7 million in 2025, compared to net cash used of $31.0 million in 2024, reflecting improved operational efficiency.
• VAZKEPA has 10 years of market protection in Europe, with a patent extending exclusivity to 2039, providing a long runway for international growth.
• Positive clinical data and scientific statements continue to support Icosapent Ethyl (IPE) for cardiovascular risk reduction, with over 70 global medical societies recognizing its use.
• The Federal Circuit reversed a district court ruling in the Hikma patent infringement lawsuit, finding Amarin's allegations plausible, though this is now under Supreme Court review.

Negatives

• Total revenue, net, decreased by 7% ($15.0 million) in 2025 compared to 2024.
• U.S. product revenue, net, decreased by 8% ($12.6 million) in 2025, primarily due to declining net selling price from generic competition.
• Amarin's share of the U.S. icosapent ethyl market decreased to approximately 47% in 2025 from 53% in 2024.
• VASCEPA-branded prescriptions in the U.S. decreased by 10% in 2025.
• The company reported a net loss of $38.8 million in 2025, continuing a trend of operating losses.
• Ongoing antitrust class action lawsuits and government investigations (DOJ, NY AG) pose significant legal and financial risks.
• The Supreme Court granted Hikma's petition to review the Federal Circuit decision, prolonging patent litigation uncertainty.

Risks

• Substantial dependence on VASCEPA sales and its commercialization in the U.S., Europe, and other major markets.
• Increasing competition from generic drug companies and non-prescription omega-3 fatty acids in the U.S., materially and adversely affecting revenues.
• Uncertainty in obtaining favorable pricing and reimbursement levels for VAZKEPA in international markets, potentially limiting patient access and commercial value.
• Factors outside of control may hinder market acceptance of VASCEPA by physicians, patients, and payors.
• The Global Restructuring Plan may not successfully mitigate risks or establish a significant international footprint.
• Regulatory oversight and scrutiny of manufacturing, supply, commercialization, and promotional activities, with potential for changes in reimbursement procedures.
• Reliance on third-party manufacturers and suppliers, including burdensome minimum purchase commitments that may exceed supply needs.
• Dependence on third parties in the distribution channel, limiting profitability and supply to market segments.
• Reliance on third parties for international efforts, with risks related to partner performance and control over activities.
• Challenges and costs in enforcing patent rights, with no assurance that issued patents will prevent competitors.
• Uncertainty regarding the issuance of pending patent applications and their sufficiency to minimize competition.
• Reliance on third parties to conduct clinical trials, with risks of unsatisfactory performance or missed deadlines.
• New clinical data or analysis of existing data could adversely impact public perception of VASCEPA's clinical profile.
• Exposure to customer concentration risk, with three customers accounting for a significant portion of gross product sales and accounts receivable.
• Ongoing litigation and government investigations are costly and divert management attention.
• Potential product liability claims related to manufacturing and marketing of VASCEPA.
• History of operating losses and uncertainty in achieving sustained profitability without additional financing.
• Share repurchase program may not be implemented or have expected results.
• Changes in tax laws or tax residence could negatively affect future profitability.
• Potential business combinations or strategic transactions may disrupt business or divert management's attention.
• Adverse impact from geopolitical instability, macroeconomic events, capital markets disruption, and trade restrictions.
• Risk of computer system failures or security breaches, including those related to artificial intelligence technologies.
• Loss of key personnel could adversely affect the business.

Future Outlook

Amarin anticipates continued operating losses for an indefinite period. The company expects quarterly net cash outflows to be variable due to API purchases, U.S. generic competition, and VAZKEPA commercialization efforts in Europe. Amarin believes its current liquidity will fund projected operations for at least 12 months, but additional capital may be required to fully realize VASCEPA's market potential. The company will continue to assess other potential partnership opportunities for VASCEPA in international markets and further analyze REDUCE-IT trial results.

Management Comments

• Management believes that the expectations reflected in the forward-looking statements are reasonable, but cannot guarantee future results, performance, or achievements.
• Management believes that its financial forecasts are reasonable and appropriate based upon current facts and circumstances, but actual results may differ.
• Management believes that its cash and cash equivalents and short-term investments will be sufficient to fund projected operations for at least one year from the issuance date of the financial statements.

Industry Context

StockSavvy.ai notes that Amarin operates in a highly competitive pharmaceutical industry, particularly in cardiovascular health. The company faces significant challenges from generic competition in the U.S., a trend impacting many branded drugs post-patent expiry. The focus on international expansion, especially in Europe and Asia, aligns with a broader industry strategy to diversify revenue streams and leverage market protection periods. The emphasis on cost-effectiveness and clinical evidence for reimbursement reflects increasing scrutiny from global payors. The failure of other omega-3 mixtures (STRENGTH trial, PROMINENT trial) to demonstrate cardiovascular benefit, unlike VASCEPA's REDUCE-IT, highlights VASCEPA's unique position but also underscores the difficulty of achieving such outcomes in the competitive landscape.

Comparison to Industry Standards

• VASCEPA is the first and only drug approved by the U.S. FDA as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG levels (150 mg/dL) and either established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease, distinguishing it from other omega-3 products.
• Unlike Lovaza/Omacor (1-gram per day) and Epanova (4-grams per day), which failed to show substantial CV benefit in outcomes trials, VASCEPA's REDUCE-IT study demonstrated a 25% relative risk reduction in major adverse cardiovascular events.
• VASCEPA's EPA-only/DHA-free composition is believed to mitigate against the LDL-C raising effect observed in omega-3 compositions that include DHA, a key differentiator from other omega-3 products like Lovaza.
• The STRENGTH trial (AstraZeneca's Epanova) and PROMINENT trial (Kowa Research Institute's pemafibrate) both failed to meet primary endpoints for CV risk reduction, reinforcing the unique positive outcomes of Amarin's REDUCE-IT study.
• The JELIS study in Japan with Epadel (ethyl-EPA) showed a 19% reduction in cardiovascular events, consistent with REDUCE-IT, further supporting the efficacy of EPA-only formulations.
• Competition from PCSK9 inhibitors (alirocumab, evolocumab, inclisiran) represents a different class of lipid-lowering agents with longer dosing intervals, indicating a diverse and evolving treatment landscape for cardiovascular risk.

Management Changes

Corporate Governance

Legal Proceedings

• Patent infringement lawsuit against Hikma Pharmaceuticals USA Inc. for inducing infringement of patents covering VASCEPA's CV risk reduction use. Federal Circuit reversed dismissal, but the U.S. Supreme Court granted Hikma's petition for review, staying District Court proceedings.
• Six antitrust class action lawsuits in the District Court for the District of New Jersey, alleging monopolization and conspiracy to restrain trade in the icosapent ethyl drug and API markets, filed by Dr. Reddy's, Hikma, Teva, Apotex, and consumer groups.
• Civil investigative demands (CIDs) from the U.S. Federal Trade Commission and a subpoena from the New York Attorney General investigating promotional speaker programs and co-payment waiver programs for potential Anti-Kickback Statute and Civil False Claims Act violations.
• Lawsuit filed by former CEO Karim Mikhail against Amarin concerning alleged constructive termination, currently in its second amended complaint stage after a motion to dismiss was granted in part.

Stakeholder Impact

• Shareholders: Affected by declining U.S. sales, ongoing litigation, and stock price volatility, but potentially benefit from international growth strategies, cost savings, and the approved share repurchase program (if commenced).
• Employees: Impacted by the Global Restructuring Plan, which eliminated commercial roles in Europe, and potential increased turnover due to generic competition and business uncertainty.
• Customers (Wholesalers/Pharmacies): Subject to changes in pricing, reimbursement policies, and generic competition, affecting their ability to stock and dispense VASCEPA.
• Patients: Access to VASCEPA may be limited by pricing and reimbursement challenges, especially outside the U.S., and by generic substitution in the U.S.
• Partners (e.g., Recordati, Edding, HLS): Their commercial success and ability to secure reimbursement directly impact Amarin's licensing and royalty revenues.

Next Steps

• Continue to work on generating revenue from partnerships in key international markets outside the Recordati Territory.
• Assess other potential partnership opportunities for VASCEPA in international markets where it receives local regulatory approval.
• Continue to negotiate with contract suppliers to align supply arrangements with current and future global market demand.
• Vigorously defend intellectual property rights related to VASCEPA in ongoing and future litigation.
• Monitor business and market conditions regarding the commencement of the $50.0 million share repurchase program.
• Continue to publish additional details of the REDUCE-IT study to address scientific interest.
• Explore potential new product and indication opportunities based on EPA in collaboration with Mochida.

Key Dates

Recommendation

Amarin faces significant headwinds from generic competition in the U.S., leading to declining revenue and market share, and is burdened by ongoing, costly litigation. However, the company is actively pursuing international expansion with VAZKEPA, which shows promise with market protection and patent exclusivity until 2039 in Europe, and has implemented a global restructuring plan to reduce operating costs. The mixed financial performance, coupled with the long-term potential of international markets and cost-saving initiatives, suggests a 'hold' recommendation for a seasoned investor, allowing time to assess the effectiveness of the international strategy and the outcomes of critical legal challenges.

Keywords

VASCEPA, VAZKEPA, Icosapent Ethyl, Cardiovascular Health, Triglycerides, REDUCE-IT, Pharmaceuticals, SEC Filing, 10-K, Generic Competition, Market Exclusivity, Regulatory Approval, Global Restructuring, Patent Litigation, JPMorgan Chase Bank, Nasdaq Capital Market